Literature DB >> 29125674

Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome: a prospective study.

Yky Cheng1, W C Leung2, T Y Leung1, K W Choy1, Rwk Chiu3, T-K Lo4, K Y Kwok1, D S Sahota1.   

Abstract

OBJECTIVE: To examine preferences for follow-up testing in women screened with high or intermediate risk for Down syndrome in the first or second trimester.
DESIGN: Prospective cohort study.
SETTING: Three public hospitals in Hong Kong, China. SAMPLE: Women with pregnancies termed as high risk (≥1:250; HR) or intermediate risk (1:251-1200; IR) for Down syndrome.
METHODS: Women with pregnancies screened as HR were offered the choices of: (1) an invasive test plus chromosomal microarray (CMA) to obtain more detailed fetal genetic information; (2) non-invasive cell-free prenatal DNA screening (NIPT) to detect trisomies 13, 18 and 21, and to avoid procedure-related miscarriage; and (3) to decline any further testing. Women received standardised counselling informing them that the reporting times were identical, the procedure miscarriage risk was 0.1-0.2% and that there was no charge for screening. Women with IR pregnancies (1:251-1200) were offered NIPT as a secondary screening test. MAIN OUTCOME MEASURES: Uptake rate for NIPT.
RESULTS: Three hundred and forty-seven women had pregnancies deemed as HR; 344 (99.1%) women opted for follow-up testing, 216 (62.2%) of whom chose NIPT. Five hundred and seven of 614 women (82.6%) with IR risk chose NIPT. Seven (21%) of 34 women with nuchal translucency ≥3.5 mm opted for NIPT.
CONCLUSION: In a setting where reporting times are similar and there is no cost difference between options, approximately 60% of women with pregnancies classed as HR would opt for NIPT, offering simple but limited aneuploidy assessment, over a diagnostic procedure with comprehensive and more detailed assessment. TWEETABLE ABSTRACT: 60% of pregnant Chinese women prefer NIPT over CMA when screened as high risk for Down syndrome.
© 2018 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Cell-free DNA; Down syndrome screening; chromosomal microarray; non-invasive prenatal DNA testing; trisomy

Mesh:

Substances:

Year:  2018        PMID: 29125674     DOI: 10.1111/1471-0528.15022

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  4 in total

1.  [Differential expression profile of miRNAs in amniotic fluid exosomes from fetuses with Down syndrome].

Authors:  K Ding; L Yu; Z Huang; H Zheng; X Yang; T Tian; R Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-02-20

2.  Women's Attitudes Toward Invasive and Noninvasive Testing When Facing a High Risk of Fetal Down Syndrome.

Authors:  Valerie Seror; Olivier L'Haridon; Laurence Bussières; Valérie Malan; Nicolas Fries; Michel Vekemans; Laurent J Salomon; Yves Ville
Journal:  JAMA Netw Open       Date:  2019-03-01

3.  Optimization Protocol of Fixation Method for Trophoblast Retrieval from the Cervix (TRIC): A Preliminary Study.

Authors:  Min Jin Lee; Soo Hyun Kim; Sung Han Shim; Hee Yeon Jang; Hee Jin Park; Dong Hyun Cha
Journal:  Diagnostics (Basel)       Date:  2020-05-14

4.  Next-generation sequencing: a follow-up of 36,913 singleton pregnancies with noninvasive prenatal testing in central China.

Authors:  Wan Lu; Ting Huang; Xin-Rong Wang; Ji-Hui Zhou; Hui-Zhen Yuan; Yan Yang; Ting-Ting Huang; Dan-Ping Liu; Yan-Qiu Liu
Journal:  J Assist Reprod Genet       Date:  2020-10-23       Impact factor: 3.412

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.